DrugPatentWatch Database Preview
Details for Patent: 7,829,121
Which drugs does patent 7,829,121 protect, and when does it expire?
Patent 7,829,121 protects AMRIX and is included in one NDA.
This patent has one patent family member in one country.
This patent has one patent family member in one country.
Summary for Patent: 7,829,121
| Title: | Modified release dosage forms of skeletal muscle relaxants |
| Abstract: | A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration--time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period. |
| Inventor(s): | Venkatesh; Gopi (Vandalia, OH), Clevenger; James M. (Vandalia, OH) |
| Assignee: | Eurand Inc. (Vandalia, OH) |
| Application Number: | 12/236,719 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 7,829,121
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | RELIEF OF MUSCLE SPASM | ➤ Sign Up | ||||
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | RELIEF OF MUSCLE SPASM | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 7,829,121
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,790,199 | Modified release dosage forms of skeletal muscle relaxants | ➤ Sign Up |
| 7,820,203 | Modified release dosage forms of skeletal muscle relaxants | ➤ Sign Up |
| 8,877,245 | Modified release dosage forms of skeletal muscle relaxants | ➤ Sign Up |
| 7,387,793 | Modified release dosage forms of skeletal muscle relaxants | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 7,829,121
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005048996 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
